• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, June 26, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Frequency and outcomes of new suspicious lesions on breast MRI in neoadjuvant therapy

Bioengineer by Bioengineer
May 7, 2019
in Cancer
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Results to be exhibited at 2019 ARRS Annual Meeting

Leesburg, VA, May 7, 2019–During neoadjuvant chemotherapy, new suspicious findings detected on breast magnetic resonance imaging (MRI) during neoadjuvant therapy are most likely benign, according to a study to be presented at the ARRS 2019 Annual Meeting, set for May 5-10 in Honolulu, HI.

The study was conducted to determine the frequency and outcomes of new suspicious lesions on breast MRI arising during neoadjuvant chemotherapy.

A retrospective database review found a total of 419 breast MRI examinations performed in 297 women to evaluate response to neoadjuvant chemotherapy. After exclusions for reasons including a lack of baseline pretreatment MRI for comparison, the final study cohort consisted of 28 MRI examinations (7%) with new suspicious findings.

All cases included in the study were assessed as BI-RADS 4. Twenty-five cases had either tissue diagnosis or adequate imaging follow-up to establish a diagnosis of the new suspicious findings on breast MRI. Of these 25 cases, 44% were proven benign at percutaneous biopsy, 20% at surgical pathology, and 36% were assessed benign based on follow-up imaging of 2 years or longer. That is, for all 25 cases the cancer yield for new suspicious lesions was 0%.

Results suggest that new suspicious finding on breast MRI which occur during neoadjuvant therapy are highly unlikely to signify a new malignancy, although the authors encourage further study to confirm whether biopsy may be safely avoided in these circumstances.

“We found that new suspicious lesions on MRI are not rare, occurring 7% of the time,” Donna Eckstein, MD, author of the study said. “Nearly all of these new lesions arose while the index tumor showed treatment response on MRI, and none of these new lesions were malignant. Larger studies across facilities are needed to confirm whether biopsy may be safely averted in these scenarios.”

###

With educational activities representing the entire spectrum of radiology, ARRS will host leading radiologists from around the world at the ARRS 2019 Annual Meeting, May 5-10, at the Hawaii Convention Center in Honolulu, Hawaii. For more information, visit: http://www.arrs.org/am19.

Media Contact
Alycia Tessean
[email protected]
https://arrs.org/ARRSLIVE/Pressroom/PressReleases/neoadjuvant-therapy-lesions-breast-mri.aspx

Tags: Breast CancercancerDiagnosticsHealth Care Systems/ServicesHealth ProfessionalsMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Cracking the Code: How Cancer Evades Antibody-Drug Conjugates and New Strategies to Overcome Resistance

June 25, 2026

MSU Scientists Reveal Mechanism Behind Ovarian Cancer’s Chemotherapy Resistance and Strategies to Overcome It

June 25, 2026

Rare Mixed Liver Cancer Underscores Diagnostic and Therapeutic Challenges

June 25, 2026

How Socioeconomic Factors Shape Lung Cancer Screening Experiences

June 25, 2026
Please login to join discussion

POPULAR NEWS

  • Saying Goodbye to PGY-6: Pediatric Fellowship Realities

    103 shares
    Share 41 Tweet 26
  • Multi-Hospital Study Reveals Long Covid Burden Is Twice as High as Current Estimates

    92 shares
    Share 36 Tweet 23
  • Detection of EDCs in Breast Milk and Infant Urine Up to Six Months Highlights Early Exposure Risks

    77 shares
    Share 31 Tweet 19
  • New Drug Candidate Developed at McMaster Shows Potential for Treating Brain Cancer

    58 shares
    Share 23 Tweet 15

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Tracking Lanthanide-Labeled Microplastics in Plants

POSTECH Researchers Slash Cost of Reconstituted Cell-Free Systems by 95%

AI and Physics Collaborate to Design Advanced Hydrogen Storage Materials

Subscribe to Blog via Email

Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm' to start subscribing.

Join 82 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.